HIV testing and window periods

01Core principlesThe concepts and mechanisms needed to understand the subject.

HIV tests detect different targets at different stages. RNA appears first, followed by p24 antigen and then antibodies. A venous laboratory fourth-generation assay combines antigen and antibody detection and therefore shortens the window compared with antibody-only rapid devices. The window is the interval after exposure by which the test is expected to detect nearly all infections, not the earliest day on which a positive result is possible.

BHIVA/BASHH 2020 sets 45 days for laboratory fourth-generation serology and 90 days for rapid point-of-care tests. Labels such as rapid, home, finger-prick and fourth generation are not interchangeable: specimen, platform and laboratory processing determine performance. The clinician must identify the actual assay used before giving a closing date.

Testing now and later answers different questions. An immediate negative result can exclude older infection and provides a baseline before PEP or PrEP, but it cannot exclude the exposure that just happened. The follow-up date should be calculated from the relevant exposure or, after PEP, from completion according to the PEP guideline. Ongoing exposure resets the clock for that exposure.

Acute HIV can be antigen-antibody negative while RNA and infectiousness are high. Fever, rash, pharyngitis, lymphadenopathy, diarrhoea, mucosal ulcers or aseptic meningitis after risk should trigger urgent RNA testing and specialist input. Two-drug PrEP must not be used as incomplete treatment while acute infection is unresolved.

A reactive screening result needs confirmatory differentiation and nucleic-acid testing because false reactivity occurs and HIV-2 or acute HIV can create discordant patterns. Communication should distinguish screening from diagnosis, preserve privacy, assess immediate distress and provide direct linkage rather than leaving the patient to navigate care alone.

Key points

A venous laboratory fourth-generation HIV-1/2 antigen-antibody assay has a 45-day window under BHIVA/BASHH guidance.
All rapid point-of-care tests use a 90-day window in the UK guideline; confirm the exact product and specimen rather than calling every rapid test fourth generation.
Test immediately after a recent exposure to detect pre-existing infection, then repeat after the relevant window; do not delay PEP while waiting.
Request HIV RNA when acute HIV is strongly suspected or recent antiretroviral prophylaxis makes serology difficult to interpret.
A reactive screen is not a final diagnosis: complete the confirmatory differentiation and nucleic-acid algorithm on a new or appropriately handled sample.
A negative result closes only the exposures that occurred before that assay window and only when PEP, PrEP or immune impairment has not changed interpretation.
Use consent and private communication, give the person an exact date for repeat testing, and assign ownership for every result.

02Mechanisms and patternsImportant relationships and how to distinguish them.

Acute retroviral syndromeRed flag

Fever, rash, sore throat, nodes, diarrhoea or meningism weeks after exposure raises acute HIV despite negative serology.

Asymptomatic screening

Many diagnoses follow routine sexual-health, antenatal, indicator-condition or opt-out testing without HIV-specific symptoms.

Indicator condition

Tuberculosis, lymphoma, recurrent shingles, oral candidiasis, cytopenia or unexplained weight loss should prompt an HIV test.

Advanced immune deficiencyRed flag

Oesophageal candidiasis, wasting, opportunistic infection or unusual neurological disease requires urgent testing and CD4 assessment.

Prophylaxis-altered patternRed flag

Recent PEP or PrEP may reduce RNA and delay antigen or antibody evolution, creating discordant results.

HIV-2 possibility

West African exposure or discordant differentiation with low HIV-1 RNA requires an HIV-2-capable specialist algorithm.

Red flags requiring action

A reactive screening assay is preliminary and requires the national confirmatory algorithm before final diagnosis is communicated.
A negative result before the assay-specific window has closed cannot exclude acquisition from the recent exposure.
Acute retroviral symptoms after recent risk require HIV RNA even when antigen, antibody or a rapid test is non-reactive.
Current or recent PrEP, PEP or ART can suppress viraemia and delay serological evolution, so specialist testing is needed.
Pregnancy, breastfeeding, organ donation, needlestick exposure or suspected advanced disease creates an urgent linked clinical pathway alongside testing.

03Interpreting evidenceInformation, measurements and their limitations.

Reasoning sequence

Consider the information, its meaning and its limitations before deciding what follows.

01
Laboratory fourth-generation HIV antigen-antibody assay
Why
Detect p24 antigen and HIV-1 or HIV-2 antibodies in venous blood.
Interpretation and limitations
A non-reactive result excludes exposures at least 45 days earlier when prophylaxis and other modifiers do not apply.
02
Rapid point-of-care HIV test
Why
Provide an accessible immediate preliminary result using the specific device and specimen.
Interpretation and limitations
Use the UK 90-day window for all rapid point-of-care tests and confirm every reactive result in the laboratory.
03
HIV-1 RNA
Why
Detect acute infection before serology or investigate discordant results and prophylaxis-altered presentations.
Interpretation and limitations
Request urgently when acute HIV is suspected; a specialist must interpret low or suppressed values after antiretroviral exposure.
04
Confirmatory differentiation algorithm
Why
Confirm a reactive screen and distinguish HIV-1, HIV-2 and false reactivity.
Interpretation and limitations
Do not label one reactive screening assay as final; use the national sequence and additional nucleic acid testing where required.
05
Baseline HIV test before PEP or PrEP
Why
Detect infection predating the reported exposure and prevent inappropriate prophylaxis.
Interpretation and limitations
Take immediately but never delay indicated PEP; an early negative baseline does not exclude the current exposure.
06
Repeat assay after window
Why
Close the diagnostic episode at the correct date for the assay and exposure.
Interpretation and limitations
Recalculate for later exposure and use the PEP-specific interval after a completed course rather than a generic date.

04Applied reasoningWorked examples connecting principles to decisions.

01Worked caseInterpret an early negative resultA person has a negative laboratory fourth-generation test 18 days after a substantial exposure and no symptoms.

1Explain that the result is reassuring for older infection but remains inside the 45-day window for the reported exposure.
2Arrange repeat laboratory testing at or after day 45 and give an exact date, while assessing whether PEP was indicated earlier or PrEP is now appropriate.
3Ask about any subsequent exposures because each creates its own closing date and prevention need.
4Verify the final result personally and document how the actual assay, specimen and prophylaxis history were considered.

02AcuteAdd RNA for symptomatic early infectionCompatible systemic symptoms develop after recent HIV exposure despite a non-reactive screen.

1Send a laboratory fourth-generation test and urgent HIV RNA and discuss the case with an HIV service.
2Do not start two-drug PrEP alone while acute infection is unresolved; use the appropriate PEP or treatment pathway for timing.
3Test alternative and coexisting diagnoses such as syphilis, hepatitis and EBV without allowing them to exclude HIV.

03ReactiveConfirm and communicate carefullyA screening assay returns reactive in any setting.

1Explain privately that the screening result requires confirmation and assess distress, self-harm, safeguarding and support needs.
2Send confirmatory differentiation and nucleic-acid tests using the national algorithm.
3Arrange direct HIV-service linkage with a named appointment and do not wait for illness to develop.

04After PEPUse the PEP testing intervalA 28-day post-exposure prophylaxis course has been completed.

1Arrange the final fourth-generation test at least 45 days after PEP completion, which is at least 73 days after exposure for a completed course.
2Investigate any acute symptoms immediately with RNA rather than waiting for the scheduled date.
3Transition ongoing risk into PrEP using specialist advice so testing and prevention continue without a gap.

05Checking understandingVerify the reasoning, revisit uncertainties and apply feedback.

Record the exact assay, specimen, exposure date and whether PEP or PrEP was taken.
Give the patient a dated repeat-test plan rather than saying only to return after the window.
Confirm every reactive result through the national algorithm and document who will communicate it.
Use HIV RNA urgently for acute symptoms or antiretroviral-altered serology.
Reassess new exposures at follow-up because they create another diagnostic window.
Link negative testing to vaccination, STI testing, condoms, PEP access and PrEP when indicated.
Review emotional wellbeing and confidentiality during both preliminary and confirmed result communication.

06Special situationsVariants, exceptions and circumstances that change the usual approach.

Window is not first detection

Some infections become reactive earlier, but a negative result closes exposure only after the validated window.

Rapid is a broad label

Device generation, specimen and processing differ, so use the actual test instructions and UK 90-day rapid-test window.

Baseline answers an older question

Testing immediately after exposure can find pre-existing HIV but cannot exclude infection from the event just reported.

RNA resolves early suspicion

Nucleic acid detection is required when a convincing acute syndrome precedes antigen and antibody positivity.

Antiretrovirals alter kinetics

PEP or PrEP can suppress viral replication and delay usual markers, requiring specialist interpretation.

Reactive means preliminary

Support and linkage should begin immediately while the confirmatory algorithm establishes the final diagnosis.

07Common pitfallsFrequent interpretation and management errors.

01
Do not call a rapid finger-prick result equivalent to a venous laboratory fourth-generation assay.
02
Do not use 45 days for every HIV test; UK rapid point-of-care tests use 90 days.
03
Do not reassure from a negative test taken inside its window.
04
Do not delay indicated PEP until a baseline result returns.
05
Do not start two-drug PrEP during unresolved acute HIV.
06
Do not communicate one reactive screening assay as a confirmed diagnosis.

Find your next topic